Before joining Labopharm, Heino held executive positions in a subsidiary of Johnson & Johnson, Centocor.
Prior to Centocor, Heino worked with Janssen Pharmaceuticals, also a subsidiary of Johnson & Johnson and held various leadership positions.
Dayno held senior executive roles at Merck followed by Cephalon, where he was the vice president of Medical Services.
Labopharm president and CEO James Howard-Tripp said as acting president of Angelini Labopharm, Mary Anne played an instrumental role in the commercial preparation for the US launch of Oleptro last August.
"Since joining Labopharm last year as chief medical officer, Jeff has demonstrated leadership across the organization and made significant contributions both to the launch of Oleptro and managing the clinical relationship with Angelini Labopharm," Howard-Tripp said.